APO Research
Talk to an analyst

APO RESEARCH · REPORT

Linagliptin DPP-4 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

Linagliptin DPP-4 Inhibitors Industry Research Report 2026

23 December 2025135 pages

Choose your research edition.

Industry ResearchLinagliptin DPP-4 Inhibitors Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Linagliptin DPP-4 Inhibitors Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Linagliptin DPP-4 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Linagliptin DPP-4 Inhibitors Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Linagliptin DPP-4 Inhibitors Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Linagliptin DPP-4 Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Linagliptin DPP-4 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Linagliptin DPP-4 Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Linagliptin DPP-4 Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Linagliptin DPP-4 Inhibitors include Yangzijiang Pharmaceutical Group, Cspc Holdings Company, MINSHENG PHARMACEUTICAL, Shandong Lukang Pharmaceutical, Eli Lilly, Sichuan Kelun Pharmaceutical, China Resources Shuanghe Pharmaceutical, Huahai Pharmaceutical and Jiangsu Deyuan Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Linagliptin DPP-4 Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Linagliptin DPP-4 Inhibitors Market by Company

Yangzijiang Pharmaceutical Group

Cspc Holdings Company

MINSHENG PHARMACEUTICAL

Shandong Lukang Pharmaceutical

Eli Lilly

Sichuan Kelun Pharmaceutical

China Resources Shuanghe Pharmaceutical

Huahai Pharmaceutical

Jiangsu Deyuan Pharmaceutical

Chengda Pharmaceuticals

Zydus

Torrent Pharmaceuticals

Mankind Pharma

Boehringer Ingelheim

Alkem Labs

Linagliptin DPP-4 Inhibitors Segment by Type

Original Drug

Generic Drug

Linagliptin DPP-4 Inhibitors Segment by Application

Hospital

Retail Pharmacy

Linagliptin DPP-4 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Linagliptin DPP-4 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Linagliptin DPP-4 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Linagliptin DPP-4 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Linagliptin DPP-4 Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Linagliptin DPP-4 Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Linagliptin DPP-4 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Linagliptin DPP-4 Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Linagliptin DPP-4 Inhibitors Sales (k units) of Manufacturers (2021-2026) Table 7. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global Linagliptin DPP-4 Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global Linagliptin DPP-4 Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Linagliptin DPP-4 Inhibitors Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global Linagliptin DPP-4 Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Linagliptin DPP-4 Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Linagliptin DPP-4 Inhibitors, Product Type & Application Table 14. Global Linagliptin DPP-4 Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Linagliptin DPP-4 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Yangzijiang Pharmaceutical Group Company Information Table 19. Yangzijiang Pharmaceutical Group Business Overview Table 20. Yangzijiang Pharmaceutical Group Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. Yangzijiang Pharmaceutical Group Linagliptin DPP-4 Inhibitors Product Portfolio Table 22. Yangzijiang Pharmaceutical Group Recent Developments Table 23. Cspc Holdings Company Company Information Table 24. Cspc Holdings Company Business Overview Table 25. Cspc Holdings Company Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Cspc Holdings Company Linagliptin DPP-4 Inhibitors Product Portfolio Table 27. Cspc Holdings Company Recent Developments Table 28. MINSHENG PHARMACEUTICAL Company Information Table 29. MINSHENG PHARMACEUTICAL Business Overview Table 30. MINSHENG PHARMACEUTICAL Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. MINSHENG PHARMACEUTICAL Linagliptin DPP-4 Inhibitors Product Portfolio Table 32. MINSHENG PHARMACEUTICAL Recent Developments Table 33. Shandong Lukang Pharmaceutical Company Information Table 34. Shandong Lukang Pharmaceutical Business Overview Table 35. Shandong Lukang Pharmaceutical Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Shandong Lukang Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio Table 37. Shandong Lukang Pharmaceutical Recent Developments Table 38. Eli Lilly Company Information Table 39. Eli Lilly Business Overview Table 40. Eli Lilly Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Eli Lilly Linagliptin DPP-4 Inhibitors Product Portfolio Table 42. Eli Lilly Recent Developments Table 43. Sichuan Kelun Pharmaceutical Company Information Table 44. Sichuan Kelun Pharmaceutical Business Overview Table 45. Sichuan Kelun Pharmaceutical Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Sichuan Kelun Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio Table 47. Sichuan Kelun Pharmaceutical Recent Developments Table 48. China Resources Shuanghe Pharmaceutical Company Information Table 49. China Resources Shuanghe Pharmaceutical Business Overview Table 50. China Resources Shuanghe Pharmaceutical Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. China Resources Shuanghe Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio Table 52. China Resources Shuanghe Pharmaceutical Recent Developments Table 53. Huahai Pharmaceutical Company Information Table 54. Huahai Pharmaceutical Business Overview Table 55. Huahai Pharmaceutical Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. Huahai Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio Table 57. Huahai Pharmaceutical Recent Developments Table 58. Jiangsu Deyuan Pharmaceutical Company Information Table 59. Jiangsu Deyuan Pharmaceutical Business Overview Table 60. Jiangsu Deyuan Pharmaceutical Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Jiangsu Deyuan Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio Table 62. Jiangsu Deyuan Pharmaceutical Recent Developments Table 63. Chengda Pharmaceuticals Company Information Table 64. Chengda Pharmaceuticals Business Overview Table 65. Chengda Pharmaceuticals Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Chengda Pharmaceuticals Linagliptin DPP-4 Inhibitors Product Portfolio Table 67. Chengda Pharmaceuticals Recent Developments Table 68. Zydus Company Information Table 69. Zydus Business Overview Table 70. Zydus Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Zydus Linagliptin DPP-4 Inhibitors Product Portfolio Table 72. Zydus Recent Developments Table 73. Torrent Pharmaceuticals Company Information Table 74. Torrent Pharmaceuticals Business Overview Table 75. Torrent Pharmaceuticals Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Torrent Pharmaceuticals Linagliptin DPP-4 Inhibitors Product Portfolio Table 77. Torrent Pharmaceuticals Recent Developments Table 78. Mankind Pharma Company Information Table 79. Mankind Pharma Business Overview Table 80. Mankind Pharma Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Mankind Pharma Linagliptin DPP-4 Inhibitors Product Portfolio Table 82. Mankind Pharma Recent Developments Table 83. Boehringer Ingelheim Company Information Table 84. Boehringer Ingelheim Business Overview Table 85. Boehringer Ingelheim Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Boehringer Ingelheim Linagliptin DPP-4 Inhibitors Product Portfolio Table 87. Boehringer Ingelheim Recent Developments Table 88. Alkem Labs Company Information Table 89. Alkem Labs Business Overview Table 90. Alkem Labs Linagliptin DPP-4 Inhibitors Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Alkem Labs Linagliptin DPP-4 Inhibitors Product Portfolio Table 92. Alkem Labs Recent Developments Table 93. Global Linagliptin DPP-4 Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Linagliptin DPP-4 Inhibitors Sales by Region (2021-2026) & (k units) Table 95. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Region (2021-2026) Table 96. Global Linagliptin DPP-4 Inhibitors Sales by Region (2027-2032) & (k units) Table 97. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Region (2027-2032) Table 98. Global Linagliptin DPP-4 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Region (2021-2026) Table 100. Global Linagliptin DPP-4 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Region (2027-2032) Table 102. North America Linagliptin DPP-4 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Linagliptin DPP-4 Inhibitors Sales by Country (2021-2026) & (k units) Table 104. North America Linagliptin DPP-4 Inhibitors Sales by Country (2027-2032) & (k units) Table 105. North America Linagliptin DPP-4 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Linagliptin DPP-4 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Linagliptin DPP-4 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Linagliptin DPP-4 Inhibitors Sales by Country (2021-2026) & (k units) Table 109. Europe Linagliptin DPP-4 Inhibitors Sales by Country (2027-2032) & (k units) Table 110. Europe Linagliptin DPP-4 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Linagliptin DPP-4 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Linagliptin DPP-4 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Linagliptin DPP-4 Inhibitors Sales by Country (2021-2026) & (k units) Table 114. Asia Pacific Linagliptin DPP-4 Inhibitors Sales by Country (2027-2032) & (k units) Table 115. Asia Pacific Linagliptin DPP-4 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Linagliptin DPP-4 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Linagliptin DPP-4 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Linagliptin DPP-4 Inhibitors Sales by Country (2021-2026) & (k units) Table 119. South America Linagliptin DPP-4 Inhibitors Sales by Country (2027-2032) & (k units) Table 120. South America Linagliptin DPP-4 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Linagliptin DPP-4 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Linagliptin DPP-4 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Linagliptin DPP-4 Inhibitors Sales by Country (2021-2026) & (k units) Table 124. Middle East and Africa Linagliptin DPP-4 Inhibitors Sales by Country (2027-2032) & (k units) Table 125. Middle East and Africa Linagliptin DPP-4 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Linagliptin DPP-4 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Linagliptin DPP-4 Inhibitors Sales by Type (2021-2026) & (k units) Table 128. Global Linagliptin DPP-4 Inhibitors Sales by Type (2027-2032) & (k units) Table 129. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Type (2021-2026) Table 130. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Type (2027-2032) Table 131. Global Linagliptin DPP-4 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Linagliptin DPP-4 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Type (2021-2026) Table 134. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Type (2027-2032) Table 135. Global Linagliptin DPP-4 Inhibitors Price by Type (2021-2026) & (USD/unit) Table 136. Global Linagliptin DPP-4 Inhibitors Price by Type (2027-2032) & (USD/unit) Table 137. Global Linagliptin DPP-4 Inhibitors Sales by Application (2021-2026) & (k units) Table 138. Global Linagliptin DPP-4 Inhibitors Sales by Application (2027-2032) & (k units) Table 139. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Application (2021-2026) Table 140. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Application (2027-2032) Table 141. Global Linagliptin DPP-4 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Linagliptin DPP-4 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Application (2021-2026) Table 144. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Application (2027-2032) Table 145. Global Linagliptin DPP-4 Inhibitors Price by Application (2021-2026) & (USD/unit) Table 146. Global Linagliptin DPP-4 Inhibitors Price by Application (2027-2032) & (USD/unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Linagliptin DPP-4 Inhibitors Distributors List Table 150. Linagliptin DPP-4 Inhibitors Customers List Table 151. Linagliptin DPP-4 Inhibitors Industry Trends Table 152. Linagliptin DPP-4 Inhibitors Industry Drivers Table 153. Linagliptin DPP-4 Inhibitors Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Linagliptin DPP-4 Inhibitors Product Image Figure 5. Global Linagliptin DPP-4 Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Linagliptin DPP-4 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global Linagliptin DPP-4 Inhibitors Sales (2021-2032) & (k units) Figure 8. Global Linagliptin DPP-4 Inhibitors Average Price (USD/unit) & (2021-2032) Figure 9. Original Drug Product Image Figure 10. Generic Drug Product Image Figure 11. Hospital Product Image Figure 12. Retail Pharmacy Product Image Figure 13. Global Linagliptin DPP-4 Inhibitors Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Linagliptin DPP-4 Inhibitors, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Linagliptin DPP-4 Inhibitors Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Linagliptin DPP-4 Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Linagliptin DPP-4 Inhibitors Sales by Region in 2025 Figure 19. Global Linagliptin DPP-4 Inhibitors Revenue by Region in 2025 Figure 20. North America Linagliptin DPP-4 Inhibitors Market Size by Country in 2025 Figure 21. North America Linagliptin DPP-4 Inhibitors Sales Market Share by Country (2021-2032) Figure 22. North America Linagliptin DPP-4 Inhibitors Revenue Market Share by Country (2021-2032) Figure 23. United States Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Mexico Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Linagliptin DPP-4 Inhibitors Market Size by Country in 2025 Figure 27. Europe Linagliptin DPP-4 Inhibitors Sales Market Share by Country (2021-2032) Figure 28. Europe Linagliptin DPP-4 Inhibitors Revenue Market Share by Country (2021-2032) Figure 29. Germany Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Russia Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Spain Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Switzerland Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Sweden Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Poland Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific Linagliptin DPP-4 Inhibitors Market Size by Country in 2025 Figure 40. Asia Pacific Linagliptin DPP-4 Inhibitors Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific Linagliptin DPP-4 Inhibitors Revenue Market Share by Country (2021-2032) Figure 42. China Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Taiwan Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America Linagliptin DPP-4 Inhibitors Market Size by Country in 2025 Figure 51. South America Linagliptin DPP-4 Inhibitors Sales Market Share by Country (2021-2032) Figure 52. South America Linagliptin DPP-4 Inhibitors Revenue Market Share by Country (2021-2032) Figure 53. Brazil Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Chile Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Colombia Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Linagliptin DPP-4 Inhibitors Market Size by Country in 2025 Figure 58. Middle East and Africa Linagliptin DPP-4 Inhibitors Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Linagliptin DPP-4 Inhibitors Revenue Market Share by Country (2021-2032) Figure 60. Egypt Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Linagliptin DPP-4 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Type (2021-2032) Figure 66. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Type (2021-2032) Figure 67. Global Linagliptin DPP-4 Inhibitors Price (USD/unit) by Type (2021-2032) Figure 68. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Application (2021-2032) Figure 69. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Application (2021-2032) Figure 70. Global Linagliptin DPP-4 Inhibitors Price (USD/unit) by Application (2021-2032) Figure 71. Linagliptin DPP-4 Inhibitors Value Chain Figure 72. Linagliptin DPP-4 Inhibitors Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Linagliptin DPP-4 Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Original Drug
  • Generic Drug
Applications
  • Hospital
  • Retail Pharmacy
Companies covered
  • Yangzijiang Pharmaceutical Group
  • Cspc Holdings Company
  • MINSHENG PHARMACEUTICAL
  • Shandong Lukang Pharmaceutical
  • Eli Lilly
  • Sichuan Kelun Pharmaceutical
  • China Resources Shuanghe Pharmaceutical
  • Huahai Pharmaceutical
  • Jiangsu Deyuan Pharmaceutical
  • Chengda Pharmaceuticals
  • Zydus
  • Torrent Pharmaceuticals
  • Mankind Pharma
  • Boehringer Ingelheim
  • Alkem Labs

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Linagliptin DPP-4 Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global Linagliptin DPP-4 Inhibitors Sales (2021-2032)
  5. 2.2.3 Global Linagliptin DPP-4 Inhibitors Market Average Price (2021-2032)
  6. 2.3 Linagliptin DPP-4 Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Original Drug
  9. 2.3.3 Generic Drug
  10. 2.4 Linagliptin DPP-4 Inhibitors by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Retail Pharmacy
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Linagliptin DPP-4 Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Linagliptin DPP-4 Inhibitors Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Linagliptin DPP-4 Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Linagliptin DPP-4 Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Linagliptin DPP-4 Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Linagliptin DPP-4 Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Linagliptin DPP-4 Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of Linagliptin DPP-4 Inhibitors, Established Date
  9. 3.9 Global Linagliptin DPP-4 Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Yangzijiang Pharmaceutical Group
  2. 4.1.1 Yangzijiang Pharmaceutical Group Company Information
  3. 4.1.2 Yangzijiang Pharmaceutical Group Business Overview
  4. 4.1.3 Yangzijiang Pharmaceutical Group Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Yangzijiang Pharmaceutical Group Linagliptin DPP-4 Inhibitors Product Portfolio
  6. 4.1.5 Yangzijiang Pharmaceutical Group Recent Developments
  7. 4.2 Cspc Holdings Company
  8. 4.2.1 Cspc Holdings Company Company Information
  9. 4.2.2 Cspc Holdings Company Business Overview
  10. 4.2.3 Cspc Holdings Company Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Cspc Holdings Company Linagliptin DPP-4 Inhibitors Product Portfolio
  12. 4.2.5 Cspc Holdings Company Recent Developments
  13. 4.3 MINSHENG PHARMACEUTICAL
  14. 4.3.1 MINSHENG PHARMACEUTICAL Company Information
  15. 4.3.2 MINSHENG PHARMACEUTICAL Business Overview
  16. 4.3.3 MINSHENG PHARMACEUTICAL Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 MINSHENG PHARMACEUTICAL Linagliptin DPP-4 Inhibitors Product Portfolio
  18. 4.3.5 MINSHENG PHARMACEUTICAL Recent Developments
  19. 4.4 Shandong Lukang Pharmaceutical
  20. 4.4.1 Shandong Lukang Pharmaceutical Company Information
  21. 4.4.2 Shandong Lukang Pharmaceutical Business Overview
  22. 4.4.3 Shandong Lukang Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Shandong Lukang Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio
  24. 4.4.5 Shandong Lukang Pharmaceutical Recent Developments
  25. 4.5 Eli Lilly
  26. 4.5.1 Eli Lilly Company Information
  27. 4.5.2 Eli Lilly Business Overview
  28. 4.5.3 Eli Lilly Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Eli Lilly Linagliptin DPP-4 Inhibitors Product Portfolio
  30. 4.5.5 Eli Lilly Recent Developments
  31. 4.6 Sichuan Kelun Pharmaceutical
  32. 4.6.1 Sichuan Kelun Pharmaceutical Company Information
  33. 4.6.2 Sichuan Kelun Pharmaceutical Business Overview
  34. 4.6.3 Sichuan Kelun Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sichuan Kelun Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio
  36. 4.6.5 Sichuan Kelun Pharmaceutical Recent Developments
  37. 4.7 China Resources Shuanghe Pharmaceutical
  38. 4.7.1 China Resources Shuanghe Pharmaceutical Company Information
  39. 4.7.2 China Resources Shuanghe Pharmaceutical Business Overview
  40. 4.7.3 China Resources Shuanghe Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 China Resources Shuanghe Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio
  42. 4.7.5 China Resources Shuanghe Pharmaceutical Recent Developments
  43. 4.8 Huahai Pharmaceutical
  44. 4.8.1 Huahai Pharmaceutical Company Information
  45. 4.8.2 Huahai Pharmaceutical Business Overview
  46. 4.8.3 Huahai Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Huahai Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio
  48. 4.8.5 Huahai Pharmaceutical Recent Developments
  49. 4.9 Jiangsu Deyuan Pharmaceutical
  50. 4.9.1 Jiangsu Deyuan Pharmaceutical Company Information
  51. 4.9.2 Jiangsu Deyuan Pharmaceutical Business Overview
  52. 4.9.3 Jiangsu Deyuan Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Jiangsu Deyuan Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio
  54. 4.9.5 Jiangsu Deyuan Pharmaceutical Recent Developments
  55. 4.10 Chengda Pharmaceuticals
  56. 4.10.1 Chengda Pharmaceuticals Company Information
  57. 4.10.2 Chengda Pharmaceuticals Business Overview
  58. 4.10.3 Chengda Pharmaceuticals Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Chengda Pharmaceuticals Linagliptin DPP-4 Inhibitors Product Portfolio
  60. 4.10.5 Chengda Pharmaceuticals Recent Developments
  61. 4.11 Zydus
  62. 4.11.1 Zydus Company Information
  63. 4.11.2 Zydus Business Overview
  64. 4.11.3 Zydus Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Zydus Linagliptin DPP-4 Inhibitors Product Portfolio
  66. 4.11.5 Zydus Recent Developments
  67. 4.12 Torrent Pharmaceuticals
  68. 4.12.1 Torrent Pharmaceuticals Company Information
  69. 4.12.2 Torrent Pharmaceuticals Business Overview
  70. 4.12.3 Torrent Pharmaceuticals Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Torrent Pharmaceuticals Linagliptin DPP-4 Inhibitors Product Portfolio
  72. 4.12.5 Torrent Pharmaceuticals Recent Developments
  73. 4.13 Mankind Pharma
  74. 4.13.1 Mankind Pharma Company Information
  75. 4.13.2 Mankind Pharma Business Overview
  76. 4.13.3 Mankind Pharma Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Mankind Pharma Linagliptin DPP-4 Inhibitors Product Portfolio
  78. 4.13.5 Mankind Pharma Recent Developments
  79. 4.14 Boehringer Ingelheim
  80. 4.14.1 Boehringer Ingelheim Company Information
  81. 4.14.2 Boehringer Ingelheim Business Overview
  82. 4.14.3 Boehringer Ingelheim Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Boehringer Ingelheim Linagliptin DPP-4 Inhibitors Product Portfolio
  84. 4.14.5 Boehringer Ingelheim Recent Developments
  85. 4.15 Alkem Labs
  86. 4.15.1 Alkem Labs Company Information
  87. 4.15.2 Alkem Labs Business Overview
  88. 4.15.3 Alkem Labs Linagliptin DPP-4 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Alkem Labs Linagliptin DPP-4 Inhibitors Product Portfolio
  90. 4.15.5 Alkem Labs Recent Developments
5 Global Linagliptin DPP-4 Inhibitors Market Scenario by Region
  1. 5.1 Global Linagliptin DPP-4 Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Linagliptin DPP-4 Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global Linagliptin DPP-4 Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global Linagliptin DPP-4 Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global Linagliptin DPP-4 Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global Linagliptin DPP-4 Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global Linagliptin DPP-4 Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America Linagliptin DPP-4 Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America Linagliptin DPP-4 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Linagliptin DPP-4 Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America Linagliptin DPP-4 Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Linagliptin DPP-4 Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe Linagliptin DPP-4 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Linagliptin DPP-4 Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe Linagliptin DPP-4 Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Linagliptin DPP-4 Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Linagliptin DPP-4 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Linagliptin DPP-4 Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Linagliptin DPP-4 Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Linagliptin DPP-4 Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America Linagliptin DPP-4 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Linagliptin DPP-4 Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America Linagliptin DPP-4 Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Linagliptin DPP-4 Inhibitors Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Linagliptin DPP-4 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Linagliptin DPP-4 Inhibitors Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Linagliptin DPP-4 Inhibitors Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Linagliptin DPP-4 Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global Linagliptin DPP-4 Inhibitors Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Linagliptin DPP-4 Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global Linagliptin DPP-4 Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global Linagliptin DPP-4 Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Linagliptin DPP-4 Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Linagliptin DPP-4 Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global Linagliptin DPP-4 Inhibitors Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Linagliptin DPP-4 Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global Linagliptin DPP-4 Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global Linagliptin DPP-4 Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Linagliptin DPP-4 Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Linagliptin DPP-4 Inhibitors Value Chain Analysis
  2. 8.1.1 Linagliptin DPP-4 Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Linagliptin DPP-4 Inhibitors Production Mode & Process
  5. 8.2 Linagliptin DPP-4 Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Linagliptin DPP-4 Inhibitors Distributors
  8. 8.2.3 Linagliptin DPP-4 Inhibitors Customers
9 Global Linagliptin DPP-4 Inhibitors Analyzing Market Dynamics
  1. 9.1 Linagliptin DPP-4 Inhibitors Industry Trends
  2. 9.2 Linagliptin DPP-4 Inhibitors Industry Drivers
  3. 9.3 Linagliptin DPP-4 Inhibitors Industry Opportunities and Challenges
  4. 9.4 Linagliptin DPP-4 Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst